tbuckley/cabot-search huggingface dataset:
Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis
Authors: Eyal Robenshtok, Anat Gafter-Gvili, Elad Goldberg, Miriam Weinberger, Moshe Yeshurun, Leonard Leibovici, Mical Paul
Journal: Journal of Clinical Oncology (2007)

Purpose To evaluate the effect of antifungal prophylaxis on all-cause mortality as primary outcome, invasive fungal infections (IFIs), and adverse events. Many studies have evaluated the role of antifungal prophylaxis in cancer patients, with inconsistent conclusions. Methods We performed a systematic review and meta-analysis of randomized, controlled trials comparing systemic antifungals with placebo, no intervention, or other antifungal agents for prophylaxis in cancer patients after chemotherapy. The Cochrane Library, MEDLINE, conference proceedings, and references were searched. Two reviewers independently appraised the quality of trials and extracted data. Results Sixty-four trials met inclusion criteria. Antifungal prophylaxis decreased all-cause mortality significantly at end of follow-up compared with placebo, no treatment, or nonsystemic antifungals (relative risk [RR], 0.84; 95% CI, 0.74 to 0.95). In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, prophylaxis reduced all-cause mortality (RR, 0.62; 95% CI, 0.45 to 0.85), fungal-related mortality, and documented IFI. In acute leukemia patients, there was a significant reduction in fungal-related mortality and documented IFI, whereas the difference in mortality was only borderline significant (RR, 0.88; 95% CI, 0.74 to 1.06). Prophylaxis with itraconazole suspension reduced documented IFI when compared with fluconazole, with no difference in survival, and at the cost of more adverse events. On the basis of two studies, posaconazole prophylaxis reduced all-cause mortality (RR, 0.74; 95% CI, 0.56 to 0.98), fungal-related mortality, and IFI when compared with fluconazole. Conclusion Antifungal prophylaxis decreases all-cause mortality significantly in patients after chemotherapy. Antifungal prophylaxis should be administered to patients undergoing allogeneic HSCT, and should probably be administered to high-risk acute leukemia patients.
Anesthesiologist's Manual of Surgical Procedures
Authors: Alexander W. Gotta
Journal: JAMA (1996)

When I began my training in anesthesiology some 35 years ago, one of the first books that I purchased was a textbook of surgery, believing then (as I am convinced now) that appropriate care of the surgical patient demands knowledgeable interaction among well-educated, trained professionals—surgeon, anesthesiologist, and operating room nurse— each with some understanding of the activities of the other. Too many anesthesiologists slink behind the great blue wall separating surgeon and anesthesiologist (the blood-brain barrier), content in an intellectual sequestrum.<i>Anesthesiologist's Manual of Surgical Procedures</i>thus has a laudable aim: to produce an informed anesthesiologist knowing the needs of surgeon and patient and able to create an anesthetic plan suitable to meet their needs. Unfortunately, the book suffers from a host of problems and the aim falls short. First, the book lacks identity. Is it a definitive textbook or a primer? At 5½ lbs and 948 pages, it should
An egg a day is not harmful
Authors: J. H. Tanne
Journal: BMJ (1999)

Two prospective studies covering almost a decade have shown that healthy people did not increase their risk of heart disease or stroke by eating one egg a day (JAMA 1999;281:1387-94).

It's not eggs but other dietary and lifestyle choices that are the problem.”Egg consumption was positively associated with smoking, lower physical activity, and a generally unhealthy eating pattern,” the researchers report.

Men and women who ate eggs were more likely to eat bacon, and …
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
Authors: Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Gerhard Held, Viola Poeschel, Samira Zeynalova, Michael Wenger, Christina Nickenig, Norma Peter, Eva Lengfelder, Bernd Metzner, Tanja Rixecker, Carsten Zwick, Michael Pfreundschuh, Marcel Reiser
Journal: Blood (2012)
Trials and tribulations
Authors: D. Julian
Journal: Cardiovascular Research (1994)

Journal Article Trials and tribulations Get access Desmond Julian Desmond Julian Flat 1, 7 Netherhall Gardens, London NW3 5RN, United Kingdom: Professor D Julian. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 28, Issue 5, May 1994, Pages 598–603, https://doi.org/10.1093/cvr/28.5.598 Published: 01 May 1994 Article history Received: 30 November 1993 Accepted: 28 January 1994 Published: 01 May 1994
Cholelithiasis: causes and treatment
Authors: K HEATON
Journal: Gut (1997)

Cholelithiasis: causes and treatment . Nakayama F. (Pp 298; illustrated; $69.00.) Tokyo: Igaku-Shoin, 1997. ISBN 4-260-14334-4.

Now and again a doctor-scientist becomes so infatuated by gallstones that he gives his or her life to them (a recent example of this rare breed is a Romanian lady). The only cure is to write a monograph. Why do people get this illness? There are many reasons, but money is not one of them. Gallstones make surgeons rich, not scientists. The trouble is gallstones don’t kill people, except the occasional academic whose grant application has been turned down for the fifth time. If they did kill people—or if they disabled people or disfigured them—there would be Chairs of Cholelithology and a Journal of Cholelithology .

The disease is certainly common enough. In some places it afflicts up to 70% of women if they live long enough. But, despite this, gallstones are a fringe discipline attracting only those of a scholarly …
THE INFLUENCE OF ISOAGGLUTININS ON THE FINAL RESULTS OF HOMOPLASTIC TRANSPLANTATIONS OF ARTERIES
Authors: Ragnvald Ingebrigtsen
Journal: The Journal of Experimental Medicine (1912)

The results in the group in which there was interagglutination differ in no striking way from those obtained in the group in which there was no interagglutination. It may be concluded, therefore, that the presence of isoagglutinins is of no importance for the final results of the homoplastic transplantation of arteries. From the conflicting evidence of the survival of muscular fibers in one case and their disappearance in many other cases, it may be concluded further that between animals of the same species there are unknown biological differences that prevent, in most instances, the survival of homoplastic transplanted arteries, although a survival does occur in some cases.
BMA criticises Benefits Agency Medical Service All GPs should be involved in commissioning BMA continues work on human rights Practising in Europe (pounds sterling)100m could be injected into GP premises Crossing professional boundaries
Authors: L. Beecham
Journal: BMJ (1996)

# BMA criticises Benefits Agency Medical Service {#article-title-2}

The BMA has been trying unsuccessfully for several months to secure improvements in the pay and terms and conditions of service for doctors working for the Benefits Agency Medical Service. If progress has not been made by 1 December the BMA council has agreed that members should be advised not to offer their services to the agency. From that date the agency will be included in the Important Notice in the BMJ. This means that doctors who are applying to work for the agency will be advised of the drawbacks.

Many doctors are contracted on a sessional basis to conduct medical examinations of claimants for benefits, particularly disability benefit, the disabled living allowance, and attendance allowance. A new form of contract has recently been issued without consultation. The BMA has objected to the fact that there is no notice of termination of contract, no disciplinary or grievance procedure, and no payment when sessions are cancelled. Doctors are required to provide their own indemnity, and the service has withdrawn the provision of chaperones to accompany doctors during examinations. This is despite the high number of complaints as the doctor is seen as the agent of the agency in withholding benefit.

In addition the service receives reports from general practitioners on a fee paid basis and has refused to accept the BMA's upgraded rate for these fees. The last pay settlement was from 1 April 1995, and the service …
Impact of pravastatin on secondary prevention of coronary artery disease in normolipidemic patients: five-year angiographical follow-up results of prospective randomized trial (PCS study)
Authors: Tsutomu Nakagawa, Tohru Kobayashi, Nobuhisa Awata, Johan H. Reiber, Shinichi Sato, Tomoko Kobayashi, Yoshihiro Takeda
Journal: Journal of the American College of Cardiology (2002)
MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Authors: Chong Chen, Yu Liu, Amy R. Rappaport, Thomas Kitzing, Nikolaus Schultz, Zhen Zhao, Aditya S. Shroff, Ross A. Dickins, Christopher R. Vakoc, James E. Bradner, Wendy Stock, Michelle M. LeBeau, Kevin M. Shannon, Scott Kogan, Johannes Zuber, Scott W. Lowe
Journal: Cancer Cell (2014)
Performance data on all surgeons in England will be published within two years
Authors: G. Iacobucci
Journal: BMJ (2012)

League tables showing the results of individual surgeons working in the NHS in England are to be published within two years, the NHS’s medical director has announced.

Bruce Keogh said that the move, backed by the health secretary, Jeremy Hunt, would drive improvements in standards by forcing surgeons to deal with performance problems in an open and transparent manner.

The BMA cautiously leant its backing to the move but warned that surgeons might be deterred from taking on complex and high risk procedures if they were judged solely by “simplistic league tables.”

The NHS mandate, published last month by the Department of Health,1 pledged to expose “variation and unacceptable practice” in the health service by publishing the results of “consultant-led …
Queries and Minor Notes.
Authors: V. A. Latham
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypersensitivity of human subjects to environmental electric and magnetic field exposure: a review of the literature.
Authors: Patrick Levallois
Journal: Environmental Health Perspectives (2002)

Hypersensitivity to exposure to electric and magnetic fields (EMFs) has been reported for nearly 20 years; however, the literature on the subject is still very limited. Nearly all the literature published concerns a dermatological syndrome that consists of mainly subjective symptoms (itching, burning, dryness) and a few objective symptoms (redness, dryness) appearing after individuals begin working with video display units and decreasing during absence from work. Case-control studies as well as some good but limited double-blind trials have not found any clear relationship between this syndrome and exposure to EMFs. A "general syndrome" with more general symptoms has been rarely described but seems to have a worse prognosis. The symptoms often associated with skin disorders are mainly of neurasthenic type and can cover a lot of nonspecific symptoms present in other atypical syndromes such as multiple chemical sensitivity or chronic fatigue. Most of these symptoms are allegedly triggered by exposure to different sources of EMFs, but there have been no valid etiological studies published on this more general syndrome. It appears that the so-called hypersensitivity to environmental electric and magnetic fields is an unclear health problem whose nature has yet to be determined.
Nebulised salbutamol in life-threatening asthma.
Authors: P B Anderson
Journal: BMJ (1979)

brought to hospital having been found unconscious at home after sniffing Evostik glue.Almost immediately on arrival at hospital he had a typical grand mal convulsion, which was controlled by 5 mg of diazepam given intravenously.He regained consciousness after 20 minutes and was detained in hospital for four days.Investigations revealed no evidence of hepatic or renal dysfunction and he was subsequently discharged home.It is not known whether this patient had indulged in glue sniffing in the past.
Microsatellite conservation, polymorphism, and GC content in shrews of the genus Sorex (Insectivora, Mammalia)
Authors: F. Balloux, E. Ecoffey, L. Fumagalli, J. Goudet, A. Wyttenbach, J. Hausser
Journal: Molecular Biology and Evolution (1998)

Microsatellite conservation, polymorphism, and GC content in shrews of the genus Sorex (Insectivora, Mammalia)
Synthetic peptide dissolves fats, helps fight cholesterol
Authors: Phil Gunby
Journal: JAMA (1982)

Houston researchers have designed a synthetic peptide that acts like a detergent to dissolve lipids and activates the lecithin:cholesterol acyltransferase (LCAT) enzyme that enables the body to rid itself of cholesterol more easily. "This could lead to a whole different approach to the prevention and treatment of atherosclerosis," suggests Antonio M. Gotto, Jr, MD, chairman of the Department of Internal Medicine, Baylor College of Medicine and Methodist Hospital. "We've been working on this for a long time." Gotto and colleagues James T. Sparrow, PhD, and Henry J. Pownall, PhD, call the peptide that they have synthesized LAP-20 (lipid-associating peptide with 20 amino acids). Testing with rabbits and monkeys at risk for atherosclerosis (because of a high-fat diet or other factors) will begin in the next few months. Some of the challenges that Gotto foresees in these animal studies and in potential application to humans are: 1. The peptide may be
Non-steroidal anti-inflammatory drugs and peptic ulcers.
Authors: P M Hallwood
Journal: BMJ (1990)

department of our hospital attend because of musculoskeletal complaints and injuries.A glance at the journals of the defence organisations reveals that such injuries are often a fruitful source of litigation.We hope that the omission oforthopaedic surgery is an error in the construction of the questionnaire used in the study rather than a reflection on its lack of teaching.
Treatment of hepatic encephalopathy: Authors' reply
Authors: Bodil Als-Nielsen, Lise L Gluud, Christian Gluud
Journal: BMJ (2004)

EDITOR—We do not agree that our Cochrane review clearly shows that lactulose is ineffective. The fact that we found no evidence of effect does not imply that there is evidence of no effect.1 It is difficult to prove that a treatment has no effect.1

A survey of 989 abstracts of Cochrane reviews …
Irritable bowel-type symptoms in spontaneous and induced constipation.
Authors: S N Marcus, K W Heaton
Journal: Gut (1987)

The prevalence and severity of irritable bowel symptoms was assessed by systematic questioning in 44 constipated volunteers, most of whom had documented slow intestinal transit. All but two had one or more of the following: passage of mucus, rectal dissatisfaction, bloating, and abdominal pain relieved by defecation. All the symptoms were more prevalent than in 17 normal volunteers or in 301 apparently healthy people studied previously. When 12 normal subjects were made constipated with loperamide all developed one or more irritable bowel symptoms. When 24 constipated subjects received effective laxative treatment the prevalence and severity of these symptoms fell markedly. The findings suggest that in some subjects the slowing down of intestinal transit is associated with irritable bowel symptoms.
Case of Tubal Abortion with Double Haematosalpinx: Operation: Recovery
Authors: A. Doran
Journal: BMJ (1891)

who had suffered from lupus of the nose and face since the age of 16.All the othler seven members of her family had died from phthisis under the age of 40.He had kept the ,disease in clleck by Donovan's triple solution and by local destruction.At the age of 81 she was attacked with acute bronchitis, and thereafter fell and sustained an intracapsular fracture of the hiip-joiint.She never really recovered from the shock and died at 84 from paralysis.A remarkable feature was that the lupus gradually subsided after the bronchitis and accident till some time before her death no diseased tissue remained.In fact, but for the prior loss of tissue, especially of the nose, no one would have supposed that slhe liad ever suffered from lupus.
Secrecy around PFI projects should be lifted
Authors: Roger Dobson
Journal: BMJ (2001)

Extensive secrecy surrounding private finance initiative (PFI) projects in the NHS should be lifted and an independent regulator appointed to review costs, according to a new report.

The report, which warns of expensive implications of the PFI for the NHS, says that the level of protection given to private investors and their investments in long term contracts is probably unique to the United Kingdom.

It warns too that the go ahead for new major projects is now seen as hingeing more on whether they can attract private funding than on need. “Over £7000m has been committed to the development and management of major NHS assets by means of PFI contracts on the basis of virtually no evidence as to the likely impact on long term service delivery. Is there …
Endoscopic submucosal dissection for early gastric cancers and large flat adenomas
Authors: Y. Onozato, H. Ishihara, H. Iizuka, N. Sohara, S. Kakizaki, S. Okamura, M. Mori
Journal: Endoscopy (2006)

Endoscopic submucosal dissection (ESD) is a new diagnostic and treatment technique for early gastric cancer (EGC). The present study aims to identify the technical feasibility, operation time, and complications associated with ESD.We reviewed the patients who underwent ESD for EGCs at Maebashi Red Cross Hospital.There were 160 patients with 171 EGCs treated by ESD. The mean age was 71.4 +/- 8.9 years (median 72). The rate for one-piece resection with tumor-free margins was 94.2 % (161/171), and was 93.2 % (82/88) for large lesions (> 20 mm) and 92.1 % (35/38) for ulcerative lesions. The median operation time was 80 min (range 10-600 min). Evidence of immediate bleeding was found in 2.9 % (5/171), delayed bleeding was seen in 7.6 % (13/171), and perforation was observed in 3.5 % (6/171) of the lesions. All patients with complications, including perforation, were successfully treated endoscopically. There were no local or distant metastases in the lesions which met our indication criteria for ESD.The present study shows the technical feasibility of ESD, which provides the capability of one-piece resection even in large and ulcerative lesions.
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus
Authors: Jean-Charles Duclos-Vallée, Cyrille Féray, Mylène Sebagh, Elina Teicher, Anne-Marie Roque-Afonso, Bruno Roche, Daniel Azoulay, René Adam, Henri Bismuth, Denis Castaing, Daniel Vittecoq, Didier Samuel
Journal: Hepatology (2007)

Liver transplantation in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is a recent indication. In a single center, we have compared the survival and severity of recurrent HCV infection after liver transplantation in HIV-HCV–coinfected and HCV-monoinfected patients. Seventy-nine patients receiving a first liver graft for HCV-related liver disease between 1999 and 2005 were included. Among them, 35 had highly active antiretroviral therapy–controlled HIV infection. All patients were monitored for HCV viral load and liver histology during the posttransplantation course. Coinfected patients were younger (43 ± 6 versus 55 ± 8 years, P &lt; 0.0001) and had a higher Model for End-Stage Liver Disease (MELD) score (18.8 ± 7.4 versus 14.8 ± 4.7; P = 0.008). The 2-year and 5-year survival rates were 73% and 51% and 91% and 81% in coinfected patients and monoinfected patients, respectively (log-rank P = 0.004). Under multivariate Cox analysis, survival was related only to the MELD score ( P = 0.03; risk ratio, 1.08; 95% confidence interval, 1.01, 1.15). Using the Kaplan-Meier method, the progression to fibrosis ≥ F2 was significantly higher in the coinfected group ( P &lt; 0.0001). Conclusion: The results of liver transplantation in HIV-HCV–coinfected patients were satisfactory in terms of survival benefit. Earlier referral of these patients to a liver transplant unit, the use of new drugs effective against HCV, and an avoidance of drug toxicity are mandatory if we are to improve the results of this challenging indication for liver transplantation. (Hepatology 2007.)
Pathogenesis and Treatment of Urinary Tract Infections
Authors: Alan H. Bennett
Journal: JAMA (1981)

This monograph thoroughly updates the author's previous work on the same subject published in 1972, entitled<i>Urinary Infections</i>. Dr Stamey has devoted more than 25 years to a careful analysis of the causes and cures of urinary tract infections in both men and women, and his clinical experience and research as well as the important work of others are systematically expounded in this volume. I cannot argue with Dr Stamey for leaving chapter 3 intact as it is indeed an "in-depth" clinical-pathological study of pyelonephritis, which has no match. Dr Stamey develops the important concept that 20% of symptomatic patients will have fewer than 100,000 bacteria per milliliter in their bladder urine and that physicians should not withhold treatment because the culture results show fewer than the "standard" 100,000 bacteria per milliliter. In the chapter "Urinary Tract Infections in Women," he further emphasizes that pathogenic bacteria present in low counts
Technical Difficulties and Evaluating e-Health Interventions
Authors: Nicholas P. Semenkovich
Journal: JAMA Internal Medicine (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal